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Abstract
Introduction At the clinical introduction of antiangiogenic agents as anticancer agents, no major toxicities were expected 
as merely just endothelial cells (ECs) in tumors would be affected. However, several (serious) toxicities became apparent, of 
which underlying mechanisms are largely unknown. We investigated to what extent sunitinib (multitargeted antiangiogenic 
tyrosine kinase inhibitor (TKI)), sorafenib (TKI) and bevacizumab [specific antibody against vascular endothelial growth 
factor (VEGF)] may impair platelet function, which might explain treatment-related bleedings.
Materials and methods In vitro, the influence of sunitinib, sorafenib, and bevacizumab on platelet aggregation, P-selectin 
expression and fibrinogen binding, platelet–EC interaction, and tyrosine phosphorylation of c-Src was studied by optical 
aggregation, flow cytometry, real-time perfusion, and western blotting. Ex vivo, platelet aggregation was analyzed in 25 
patients upon sunitinib or bevacizumab treatment. Concentrations of sunitinib, VEGF, and platelet and EC activation mark-
ers were measured by LC–MS/MS and ELISA.
Results In vitro, sunitinib and sorafenib significantly inhibited platelet aggregation (20 μM sunitinib: 71.3%, p < 0.001; 
25 μM sorafenib: 55.8%, p = 0.042). Sorafenib and sunitinib significantly inhibited P-selectin expression on platelets. Expo-
sure to both TKIs resulted in a reduced tyrosine phosphorylation of c-Src. Ex vivo, within 24 h sunitinib impaired platelet 
aggregation (83.0%, p = 0.001, N = 8). Plasma concentrations of sunitinib, VEGF, and platelet/EC activation markers were 
not correlated with disturbed aggregation. In contrast, bevacizumab only significantly impaired platelet aggregation in vitro 
at high concentrations, but not ex vivo.
Conclusion Sunitinib significantly inhibits platelet aggregation in patients already after 24 h of first administration, whereas 
bevacizumab had no effect on aggregation. These findings may explain the clinically observed bleedings during treatment 
with antiangiogenic TKIs.
Keywords Platelet function · TKIs · VEGF · Bleeding
Introduction
Interference with vascular endothelial growth factor (VEGF) 
signaling and subsequent tumor neovascularization by the 
use of targeted agents has shown beneficial effects for 
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patients with various tumor types [1–5]. Specific anti-
body-based VEGF inhibitors, like bevacizumab, have been 
developed, as well as small-molecule antiangiogenic mul-
tityrosine kinase inhibitors (TKIs) interfering with VEGF 
signaling, like sunitinib and sorafenib. It was not expected 
that these antiangiogenic agents would cause severe toxici-
ties, as merely non-quiescent endothelial cells (ECs) pre-
sent in the tumor would be disturbed [6]. However, several 
(major) bleeding complications, such as subungual splinter 
hemorrhage, epistaxis, and gastrointestinal, pulmonary, and 
intracerebral bleedings, have been clinically observed (all-
grade bleeding events: sunitinib: 19.3%, sorafenib: 13.5%, 
bevacizumab: 25.0–30.4%; high-grade bleeding events: 
sunitinib: 3.0%, sorafenib: 2.2%, bevacizumab: 2.8–3.5%) 
[7–14]. Of the observed bleeding events, splinter bleedings 
are more frequently seen during TKI treatment.
The underlying mechanisms of these treatment-related 
bleeding complications have not been elucidated yet.
For adequate coagulation, coagulation factors and 
enzymes, ECs and platelets (thrombocytes) are important 
[15]. Platelets play a specific role in clot formation, because 
they immediately adhere to the damaged endothelial layer 
of the vessel wall upon detection of a breach, where they 
become activated, aggregate and release their content [15, 
16]. Relatively small differences in this orchestrated inter-
play may cause significant disturbances leading to bleeding 
complications.
It has become apparent that platelets not only play a 
role in arrest of bleeding but are also involved in vascular 
integrity and vessel repair [17, 18]. Since VEGF is crucial 
for maintaining the integrity of the microvasculature, it has 
been postulated that blockade of the VEGF pathway leads 
to compromised capacity of ECs for cell repair [17, 19, 20], 
which has been proposed as a mechanism for the observed 
vascular toxicity. Previously, we found that VEGF is trans-
ported by platelets and released upon platelet activation [21]. 
In addition, it became apparent that bevacizumab is taken up 
by platelets and neutralizes circulating platelet-VEGF [22]. 
Based on these findings and the clinically observed bleeding 
complications, we hypothesized that antiangiogenic treat-
ment may disturb platelet function which may be the cause 
behind the bleeding complications. To study this hypothesis, 
we evaluated the influence of the antiangiogenic agents suni-
tinib, sorafenib, and bevacizumab on platelet function both 
in vitro and ex vivo using platelets from patients with renal 
cell carcinoma (RCC) and non-small cell lung carcinoma 
(NSCLC).
Materials and methods
Detailed information is described in supplementary Materi-
als and methods.
Healthy volunteers
Informed consent was obtained before blood collection. 
Healthy volunteers did not take any medication in the 
prior 10 days. In vitro experiments were performed to 
study the effect of sunibitinib (10 or 20 μM), sorafenib 
(5, 10, 25 μM), and bevacizumab (50, 100 or 250 μg/ml) 
on platelet aggregation. Clinically achieved concentra-
tions for sunitinib (50 mg/day) are approximately 65 ng/ml 
(0.16 μM) [23], for sorafenib (400 mg bid) around 5 mg/l 
(10.7 μM) [24, 25], and for bevacizumab (10 mg/kg) up to 
300 μg/ml [26]. We chose these high concentrations with 
regard to the relative short incubation time. Furthermore, 
the influence of the angiogenesis inhibitors was examined 
on platelet–EC adhesion (measured by real-time perfu-
sion) and on surface P-selectin expression and fibrinogen 
binding to αIIbβ3 (measured by flow cytometry). Finally, 
tyrosine phosphorylation of Src was studied in the pres-
ence of both TKIs sunitinib and sorafenib (measured by 
western blotting).
Additional information regarding used reagents and 
antibodies and the methods used is described in supple-
mentary materials and methods.
Patients
Blood was drawn by venipuncture from patients with 
RCC before and during treatment with sunitinib and in 
patients with NSCLC before and after a single adminis-
tration of bevacizumab. The studies were approved by the 
institutional review boards. Patients were required to sign 
informed consent prior to participation.
Time points for collection of blood in patients treated 
with sunitinib were: pretreatment, 24 h, 3 weeks, and 
6  weeks after start of treatment. Platelet aggregation 
experiments and measurements of the concentrations of 
sunitinib [measured by liquid chromatography–tandem 
mass spectrometry (LC–MS/MS)], of VEGF, and of the 
activation markers of platelets and ECs [measured by 
enzyme-linked immunosorbent assay (ELISA)] were per-
formed at the different time points. Treatment-related tox-
icity was reported during the first 6 weeks of treatment 
with sunitinib. Common Terminology Criteria for Adverse 
Events (CTCAE) were used to grade bleeding events.
Treatment with chemotherapy or biologicals was not 
allowed in the previous 28 days before start sunitinib.
Time points for collection of blood samples in patients 
treated with bevacizumab were: before, and 5 h and 3 to 
5 days after the administration of bevacizumab. Prior to 
their scheduled therapy, these patients received a single 
dose of 15 mg/kg bevacizumab as part of an imaging study 
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[27]. In this study, a week prior to infusion patients under-
went a dynamic PET-CT study with both [15O]H2O and 
[11C]docetaxel. Platelet aggregation was performed at the 
different time points.
Additional information regarding the methods used is 
described in supplementary methods.
Statistical analysis
For statistical analysis, SPSS (version 21.0; SPSS INC., Chi-
gaco, IL, USA) was used. Paired t tests were performed to 
compare the absolute values of aggregation levels, the con-
centration of platelet and EC activation markers, the VEGF 
concentrations and the platelet counts over time, and the 
expression of P-selectin on the platelet membrane and the 
fibrinogen binding to GPIIb/IIIa. Independent-sample t tests 
were performed to compare impaired platelet aggregation 
in patients with and without bleeding events. With the Pear-
son correlation coefficient, the concentrations of sunitinib in 
plasma and serum and the changes in platelet counts were 
correlated with impaired platelet aggregation. In addition, 
the concentrations of platelet activation markers were cor-
related with platelet counts. Defined significance level is 
p < 0.05. Reported p values are two-sided.
Results
In vitro
Inhibition of platelet aggregation upon in vitro exposure 
to sunitinib, sorafenib, and bevacizumab
Platelet aggregation was impaired in vitro when platelets 
of healthy volunteers were pre-incubated with sunitinib, 
sorafenib, and bevacizumab and activated by collagen or 
ADP (Fig. 1a, b). Collagen-induced platelet aggregation 
was decreased with 39.4% (range 28.6–59.3, p = 0.019) and 
71.3% (range 58.2–87.0, p < 0.001) by 10 and 20 μM suni-
tinib, respectively. Sorafenib significantly impaired platelet 
aggregation at a dose of 5, 10, and 25 μM with 68.6% (range 
41.0–84.6, p = 0.002), 62.4% (range 42.6–85.7, p = 0.005), 
and 55.8% (range 49.1–62.3, p  =  0.042), respectively. 
Bevacizumab impaired the collagen activating pathway of 
platelets, dose dependently, by 40.3% (range 19.2–70.6, 
p = 0.003) at the highest used concentration of 250 μg/ml, 
but no significant inhibition at lower concentrations of beva-
cizumab was detected (Fig. 1b).
ADP-induced platelet aggregation was inhibited by 
50.8% when exposed to 20 μM sunitinib (range 30.9–80.2, 
p = 0.098), by 51.5% (range 23.3–90.8, p = 0.067) when 
exposed to 5 μM sorafenib and by 46.4% (range 0–78.3, 
p = 0.042) when exposed to 250 μg/ml bevacizumab, 
respectively (Fig. 1b).
No significant inhibition of aggregation or agglutina-
tion was observed with the agonists thrombin, arachidonic 
acid, or ristocetin/vWF (Fig. 1c).
Impact of sunitinib and sorafenib on agonist‑induced 
P‑selectin expression and fibrinogen binding
In the presence of sunitinib, significant inhibition of 
P-selectin expression, as a measure of granule secre-
tion, was observed after both ADP- and CRP-xL-induced 
platelet activation, but not with PAR1-AP as agonist 
(Fig. 2a–c). Interestingly, sunitinib also seemed to affect 
basal P-selectin expression of unstimulated platelets (data 
not shown). In the presence of sorafenib, we observed a 
significant inhibition of P-selectin expression after activa-
tion of platelets by ADP, CRP-xL, and PAR1-AP. Bevaci-
zumab had no effect on P-selectin expression. Fibrinogen 
binding to GPIIb/IIIa was significantly disturbed due to 
the presence of sorafenib after activation of platelets with 
PAR1-AP, but not with ADP or CRP-xL (Fig. 2d–f). Beva-
cizumab and sunitinib had no effect on fibrinogen binding.
No disturbance of platelet–endothelial cell interaction 
after incubation with sunitinib sorafenib or bevacizumab
To investigate whether sunitinib, sorafenib, and bevaci-
zumab interfere with the interaction between platelets 
and ECs, we studied this interaction by real-time perfu-
sion. Platelet adherence to secreted vWF strings was not 
compromised by incubation of platelets with 5 or 10 μM 
sunitinib, with 10 μM sorafenib or with 100 or 250 μg/ml 
bevacizumab compared to control conditions (Supplemen-
tal Fig. 1). In addition, pre-incubation of ECs with 5 μM 
sunitinib did not alter the interaction between platelets and 
ECs. These data suggest that the antiangiogenic agents do 
not interfere with the interaction between platelets and 
ECs.
Analysis of phosphorylation of c‑Src in platelets 
in the presence of sunitinib and sorafenib
Since sunitinib and sorafenib are multitargeted tyrosine 
kinase inhibitors, we studied whether these TKIs were able 
to inhibit tyrosine phosphorylation in platelets. Indeed, a 
small reduction in the phosphorylation of the tyrosine kinase 
c-Src was observed in the presence of sunitinib (20 µM) or 
sorafenib(25 µM) after activation of platelets with collagen 
by Western blotting (Supplemental Fig. 2).
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Ex vivo
Inhibition of platelet aggregation ex vivo during sunitinib 
and bevacizumab treatment
Patient characteristics and platelet counts are shown in 
Table 1. Seventeen patients with RCC and eight patients 
with NSCLC were included in the study prior to start of 
treatment with sunitinib or prior to the single administration 
of bevacizumab, respectively. Additional clinical informa-
tion can be found in supplementary data. Platelet aggrega-
tion could not be studied with the platelet agonist collagen in 
9 out of 17 RCC patients (technical problems in two patients; 
predefined 30% baseline aggregation level was not reached 
before start of treatment in seven patients (one patient had a 
platelet count < 1 × 1011 platelets/L). In 4 out of 17 patients, 
Fig. 1  Disturbance of platelet aggregation due to antiangiogenic treat-
ment with sunitinib, sorafenib and bevacizumab in vitro. a Represent-
ative aggregation curves of in vitro platelet aggregation experiments 
with collagen after incubation of platelets with sunitinib, sorafenib or 
bevacizumab.(Left graph: 0, 10, 20 μM sunitinib, middle graph: 0, 5, 
10, 25  μM sorafenib, right graph: 0, 100, 250  μg/ml bevacizumab). 
On the X-axis time is represented in minutes. On the Y-axis the per-
centage of aggregation is represented. b In vitro platelet aggregation 
after incubation with sunitinib, sorafenib or bevacizumab. Platelets 
were activated with collagen (0.25–1.0 μg/ml) or ADP (2.5–10 μM) 
(N = 3–6). On the X-axis the concentration of the angiogenesis inhib-
itor is represented, on the Y-axis the percentage of aggregation com-
pared to control. c In vitro platelet aggregation induced by thrombin 
(0.125–0.25  U/ml), arachidonic acid (0.25  mM) or ristocetin/vWF 
(25 mg/ml/5 μ/ml) after incubation with sunitinib, sorafenib or beva-
cizumab (N = 3–5). On the X-axis the concentration of the angiogen-
esis inhibitor is represented, on the Y-axis the percentage of aggrega-
tion compared to control. The error bars represent the standard error 
of mean. * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001
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the baseline aggregation level was not reached with ADP 
(one patient had a platelet count < 1 × 1011 platelets/L) and 
in two patients technical problems disabled the analysis. In 
two out of eight NSCLC patients receiving bevacizumab, the 
30% baseline aggregation level was not reached with colla-
gen before start of treatment, and in one patient the baseline 
aggregation level was not reached with ADP (Supplemental 
Table 1A, B).
Twenty-four hours after start of sunitinib treatment, sig-
nificantly inhibited platelet aggregation was observed for 
collagen stimulated platelets: 83.0% inhibition (mean, range 
minus 9.2–plus 100.0%, p = 0.001, N = 8 patients), and 
for ADP, 40.0% inhibition (mean, range minus 13.3–plus 
100.0%, p = 0.011, N = 11), respectively (Fig. 3a). Three 
weeks after start of treatment, platelet aggregation was 
impaired with 53.7% (mean, range minus 52.5–plus 100.0%, 
p = 0.077, N = 5) and with 56.4% (mean, range minus 
22.9–plus 100.0%, p = 0.041, N = 7) in case of stimulation 
with collagen and ADP, respectively (Fig. 3a). This inhi-
bition was still observed after the two regular stop-weeks 
of sunitinib treatment (data not shown). Change in platelet 
counts was not significantly correlated with impaired platelet 
aggregation at 3 weeks after start of treatment (correlation 
coefficient with collagen: − 0.452, p = 0.445; correlation 
coefficient with ADP: − 0.419, p = 0.349).
Five hours and 3–5 days after the administered dose of 
bevacizumab, no significant inhibition of platelet aggrega-
tion was detected upon stimulation with collagen: at 5 h 
minus 2.5% inhibition (mean, range minus 41.3–plus 78.6%, 
p = 0.964, N = 4) and at 3 to 5 days minus 5.4% inhibi-
tion (mean, range minus 52.2–plus 39.3% p = 0.835, N = 6) 
(Fig. 3b). For ADP stimulation, at 5 h after administration 
of bevacizumab and at 3 to 5 days after the administra-
tion of bevacizumab, 10.8% inhibition (mean, range minus 
49.0–plus 59.2%, p = 0.473, N = 5) and 23.3% inhibition 
Fig. 2  In vitro expression of P-selectin and binding of fibrinogen on 
platelets after platelet activation by ADP, CRP-xL or PAR-1 activat-
ing peptide in the presence of sunitinib, sorafenib and bevacizumab. 
a Expression of P-selectin after activation of platelets with ADP. b 
Expression of P-selectin after activation of platelets with CRP-xL. c 
Expression of P-selectin after activation of platelets with PAR-1 AP. 
d Fibrinogen binding after activation of platelets with ADP. e Fibrin-
ogen binding after activation of platelets with CRP-xL. f Fibrinogen 
binding after activation of platelets with PAR-1 AP. On the X-axis 
are the log scales of the concentrations of the agonists used (ADP: 
µM, CRP-xL: ng/ml, PAR-1 AP: µM). On the Y-axis the median fluo-
rescence intensity is expressed. N = 4. The error bars represent the 
standard deviation. Sunitinib: * = p ≤ 0.05, ** = p ≤ 0.01. Sorafenib: 
§ = p ≤ 0.05, §§ = p ≤ 0.01, §§§ = p ≤ 0.001
Table 1  Baseline demographics and bleeding events of patients 
treated with sunitinib and bevacizumab
Renal cell cancer (RCC), non-small cell lung carcinoma (NSCLC)




Mean age in years (range) 59 (42–73) 57 (47–70)
RCC 17 0
NSCLC 0 8
Mean platelet count pretreat-
ment * 109 (range)
359 (49–930) 212 (106–324)
Bleeding event 8 –
Grade one 6 –
Grade three 1 –
Grade four 1 –
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(mean, range minus 8–plus 82.2, p = 0.072, N = 7) were 
observed (Fig. 3b).
Bleeding events
Within the first 6 weeks after start of sunitinib treatment, 6 
out of 17 patients experienced a bleeding event. One patient 
had both epistaxis (grade three) and hematuria (grade one). 
This patient used a low molecular weight heparin (LMWH) 
among the co-medication. Another patient with intracranial 
metastases developed intracranial hemorrhage (grade four). 
All other events were grade-one bleedings: epistaxis (N = 2), 
both epistaxis and splinter bleeding (N = 1), hematoma at 
the injection site of LMWH (N = 1). No relation between 
these bleeding events and impaired platelet aggregation was 
found at 3 weeks after start of treatment. For bevacizumab, 
this analysis was not performed since platelet aggregation 
was not significantly reduced.
Plasma and serum concentrations of sunitinib in relation 
to platelet aggregation
The plasma and serum concentrations of sunitinib are shown 
in Supplemental Table 2. Twenty-four hours and 3 weeks 
after start of treatment, the plasma concentrations were 78.3 
(range 20.1–146.6) and 151.8 nM (range 36.9–248.7.0), 
and the serum concentrations 99.2 (range 29.9–205.3) 
and 191.0 nM (range 35.6–291.1), respectively, which is 
comparable to prior reports [28]. Sunitinib was still partially 
detectable after two regular stop-weeks (plasma: 25.3 nM, 
serum: 51.4 nM). The plasma and serum concentrations 
Fig. 3  Influence on platelet aggregation of the antiangiogenic agents 
sunitinib and bevacizumab in patients. a Ex vivo platelet aggregation 
24 h and 3 weeks after the first administration of sunitinib. PRP was 
activated with ADP (2.5–10  μM) or collagen (0.25–1.0  μg/ml). On 
the X-axis the time points are represented, on the Y-axis the percent-
age of aggregation compared to pretreatment (Collagen: pretreatment 
N = 8; 24 h N = 8, 3wk N = 5. ADP; pretreatment N = 11; 24 h: 
N = 11; 3wk N = 7)*. b Ex vivo platelet aggregation on day one, and 
3 to 5  days after the administration of bevacizumab. PRP was acti-
vated with ADP or collagen. On the X-axis the time points are repre-
sented, on the Y-axis the percentage of aggregation compared to pre-
treatment (Collagen: pretreatment N = 6, 5 h: N = 4, 3–5 days: N = 6. 
ADP: pretreatment N = 7, 5 h: N = 5, 3–5 days N = 7). The error bars 
represent the standard error of mean. * = p ≤ 0.05, *** = p ≤ 0.001. 
*One patient with sunitinib had thrombocytosis, and we were unable 
to dilute the PRP beneath 6 × 1011 platelets/L (we therefore kept the 
concentration equivalent for all visits)
Table 2  Concentrations of VEGF and activation markers of platelets 
and endothelial cells measured in plasma of patients before, 24 h and 
3 weeks after start of treatment with sunitinib
Vascular endothelial growth factor (VEGF), platelet poor plasma 
(PPP), von Willebrand factor (vWF), beta-thromboglobulin (beta-TG)
N is the number of patients, SEM is the standard error of mean
Pre-Tx 24 h 3 week
VEGF in PPP (pg/ml) 101 110 218
 N 17 17 9
 SEM 18 23 72
vWF (μg/ml) 16.4 15.6 15.1
 N 15 15 8
 SEM 2.1 2.1 1.7
P-selectin (ng/ml) 120.1 154.3 92.4
 N 15 15 8
 SEM 13.2 32.5 10.4
Beta-TG (ng/ml) 39.1 36.8 26.9
 N 15 15 8
 SEM 5.2 7.4 6.3
RANTES (ng/ml) 4.3 4.1 3.2
 N 15 15 8
 SEM 0.6 0.8 0.7
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were not significantly correlated with the extent of impaired 
platelet aggregation.
Activation markers of platelets and endothelial cells 
during sunitinib treatment as measured by ELISA
Plasma concentrations of activation markers of platelets 
(beta-TG, RANTES, P-selectin) and ECs (vWF) in patients 
before and during sunitinib treatment are depicted in 
Table 2. The EC marker OPG was undetectable. No cor-
relation between platelet markers and platelet counts was 
detected at 24 h. At 3 weeks, the concentration of beta-TG 
was significantly correlated with platelet count (correlation 
coefficient 0.986, p = 0.014). The concentration of plate-
let and EC markers did not significantly change during the 
course of treatment.
VEGF concentrations during treatment with sunitinib 
associated with platelet aggregation
VEGF concentrations in PPP before and during sunitinib 
treatment are shown in Table 2. Three weeks after start of 
treatment, the mean VEGF concentration was significantly 
increased compared to pretreatment (218  pg/ml (range 
63–752) versus 101 pg/ml (range 23–262), p = 0.03). Dur-
ing the two regular stop-weeks, the concentration returned 
to the pretreatment value (79 pg/ml (range 28–214)). No 
significant changes in VEGF concentration were observed 
in serum (pretreatment: 960 pg/ml (range 94–1894), 24 h: 
929 pg/ml (range 179–1787), 3 weeks: 956 pg/ml (range 
464–1611), and 6 weeks: 668 pg/ml (range 279–862)), 
respectively. VEGF levels were also measured in isolated 
platelets of these patients. Pretreatment, 24 h, 3 weeks, and 
6 weeks after start of treatment, VEGF was 139 pg per mg 
total protein (pg/mg TP) (range 26–475), 221 pg/mg TP 
(range 20–609), 133 pg/mg TP (range 11–242), and 149 pg/
mg TP (range 33–315), respectively. Already at 24 h, an 
increased VEGF level was detected compared to the pre-
treatment level (p = 0.005). VEGF concentrations were not 
correlated with the extent of impaired platelet aggregation.
Discussion
In this study, we investigated the hypothesis that targeted 
agents inhibiting VEGF signaling may disturb the function 
of platelets, thereby contributing to the observed treat-
ment-related bleeding complications. We found in vitro 
that platelet aggregation, induced by collagen or ADP, is 
reduced by the TKIs sunitinib and sorafenib. Sunitinib 
impaired platelet function in patients as well, most likely 
due to a direct effect on platelets as no correlation was 
found with decreased platelet count (a known side-effect) 
[23]. In contrast, no effect of bevacizumab (monoclo-
nal antibody against VEGF) on platelet aggregation was 
detected in patients, and only high concentrations had an 
inhibitory effect in vitro.
Within 24 h after patients started treatment with sunitinib, 
platelet aggregation was impaired by almost 50%. Approxi-
mately 35% of the patients (6 out of 17) experienced a bleed-
ing complication within the first 6 weeks of sunitinib treat-
ment. All-grade bleeding events observed in our study were 
higher than the percentages reported in the phase III study 
in patients with RCC (12%) [3] and in the phase III trial in 
GIST patients (7%) [4]. Interestingly, approximately 12% 
(2 out of 17) patients presented with a grade ≥ 3 bleeding 
event, which is remarkably higher than previously reported 
[3]. For this increased risk of high-grade bleeding compli-
cations, several possible explanations can be suggested: 
the bias introduced by the limited number of participating 
patients, or conversely, our data reflect more the frequency 
among real-world patients. An additional factor may be the 
difference in grading of bleeding events [12].
In vitro, no effect of sunitinib, sorafenib, or bevacizumab 
was observed on platelet aggregation induced by thrombin, 
arachidonic acid, or ristocetin/vWF. This might be explained 
by the fact that part of the collagen signaling pathway is 
routed via ADP signaling. Our results of the observed effect 
of sunitinib on platelet aggregation induced by collagen or 
ADP, but not by thrombin or arachidonic acid, are compliant 
with recently published data by Sabrkhany et al. [29].
To examine whether the impaired platelet aggregation 
is caused by a defect in platelet aggregation or platelet 
secretion, we analyzed the amount of P-selectin expressed 
on the membranes of activated platelets and of fibrinogen 
binding to GPIIb/IIIa. Significantly impaired expression of 
P-selectin was observed in the presence of sorafenib and 
to lesser extent of sunitinib, as compared to control condi-
tions. Fibrinogen expression was only significantly reduced 
by sorafenib after platelet activation by PAR1-activating 
peptide. Bevacizumab had no effect on P-selectin expres-
sion or fibrinogen binding. These results indicate that dis-
turbed secretion of the platelet content contributes to the 
decline in platelet aggregation [30]. In the patients treated 
with sunitinib, plasma concentrations of activation mark-
ers of platelets (P-selectin, beta-TG, RANTES) and of ECs 
(vWF) within the first six treatment weeks remained similar, 
while in contrast to the in vitro experiment, these platelets 
were not activated. These results might suggest an intact 
interaction between platelets and activated ECs, which is 
further supported by the in vitro observation that incuba-
tion of platelets with sunitinib or bevacizumab did not alter 
platelet adherence to ECs. This observation is indicative for 
the complex differential biology of platelet aggregation and 
platelet adherence to the endothelial cell layer of the vas-
cular wall.
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Interestingly, serum concentrations of sunitinib were 
higher compared to plasma at 24 h and 3 weeks after start 
of treatment. These results indicate that intracellular accu-
mulation of sunitinib occurs not only in cancer cells [31] but 
in platelets as well [29]. Due to accumulation, it may exert 
direct effects on platelet signaling, which might resemble 
data concerning the effect of other TKIs on platelet signal-
ing [16, 32–36].
While high concentrations of bevacizumab had some 
inhibitory effect on platelet aggregation in vitro, no sig-
nificant inhibition was observed with platelets of patients 
up to 5 days after administration of the highest approved 
dose of bevacizumab. These findings may provide further 
insight in antiangiogenic treatment-related toxicities, and 
in the interplay of platelets and ECs to maintain vascular 
integrity. The observation that bevacizumab did not affect 
platelet function is in line with a previous report [37], as a 
dose range of bevacizumab in vitro failed to affect platelet 
aggregation. However, the effect of bevacizumab on plate-
let aggregation still remains controversial. Meyer et al. [38] 
concluded that bevacizumab can induce platelet aggregation 
and consequently degranulation through complex formation 
with VEGF and activation of the platelet FcγRIIa receptor, 
postulating that this might explain the observed thrombotic 
events. One possible explanation for these contradictory 
results could be artificial differences and bias introduced by 
the different pre-analytical and laboratory methods used for 
the analyses, such as used type of needle, type of anticoagu-
lant, type of centrifuge and assay method, temperature dur-
ing preparation, and the center performing the analysis [39, 
40]. These discrepancies underline the undoubtedly intri-
cate and multifactorial mechanisms that can cause vascular 
events in patients with cancer.
Significant changes in VEGF concentrations in patients 
were observed during a treatment cycle of sunitinib, which 
is in line with a previous report [41], in which the authors 
speculate that this effect is secondary to increased activity 
of HIF-1α, leading to treatment-related increases in tumor 
hypoxia. We have previously reported that VEGF is almost 
completely neutralized in PRP of patients after a single 
administration of bevacizumab [27]. Now we report that 
bevacizumab does not significantly inhibit platelet aggrega-
tion in these patients, indicating that VEGF has a limited 
role in the process of platelet aggregation. This finding is 
supported by previous reports indicating that only very high 
VEGF concentrations can contribute to platelet aggregation 
[42]. In contrast, several TKIs targeting other pathways than 
the VEGF signaling pathway have been shown to exert a 
negative effect on platelet aggregation as well [16, 32–36]. 
In one of these reports, it was suggested that inhibition of Src 
family kinases (SFKs), which are among other signaling pro-
teins involved in platelet activation, might play an important 
role by affecting immunoreceptor tyrosine-based activation 
motif (ITAM) signaling [34]. Sunitinib is a very potent c-Src 
inhibitor, with approximately 60% inhibition at a concentra-
tion of 0.5 μM [43]. This effect might be further potentiated 
by increased intracellular concentrations, resulting in even 
more profound inhibition and therefore pronounced impair-
ment of platelet aggregation. We detected lower tyrosine 
phosphorylation in platelets upon TKI incubation compared 
to control conditions. More studies are required to elucidate 
whether the influence of TKIs on tyrosine phosphorylation 
might underlie impaired platelet aggregation resulting in 
bleeding events.
To conclude, treatment with sunitinib significantly inhib-
its platelet aggregation in patients already from the first day 
of treatment, while no significant inhibition was observed 
by bevacizumab. We found potential evidence that impaired 
platelet function due to antiangiogenic TKI treatment might 
play a role in clinically observed bleedings. This insight 
might contribute to the development of new targeted agents 
with a reduced risk of treatment-related toxicity.
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